Intellectual Property Rights Archives - Page 12 of 41

$1.3 Billion Johnson & Johnson COVID-19 Vaccine Development Contract Contains Broad Redactions Relating to Public’s Rights in Inventions

Posted on April 1, 2021 by Kathryn Ardizzone

On March 31, 2020, KEI received a copy of the contract between Johnson & Johnson (“J&J”) and the Department of Health and Human Services (HHS) for the development of J&J’s COVID-19 vaccine.The contract, which is now valued at $1.3 billion,… Continue Reading →

KEI Briefing Note 2021:2 Canadian Experience with Compulsory Licensing under the Canadian Access to Medicines Regime

Canadian Experience with Compulsory Licensing under the Canadian Access to Medicines Regime KEI Briefing Note 2021:2 31 March 2021 Arianna Schouten PDF available here: KEI-Briefing-Note-2021-2-CAMR-Canadian-Compulsory-Licensing

License to NIH Spike Protein Technology Needed in COVID-19 Vaccines Demonstrates “Available to the Public on Reasonable Terms” Requirement

Posted on March 30, 2021 by Kathryn Ardizzone

A March 21, 2021 New York Times article on vaccine access discusses how a technology invented and owned by the National Institutes of Health (NIH) is necessary to make several COVID-19 vaccines. The invention mentioned by the Times, titled Prefusion… Continue Reading →

Negotiations on the 74th World Health Assembly (WHA) resolution on local production

Negotiating texts for WHA 74 on local production. 4 December 2020. Concept Note (Text prepared by Ethiopia) Zero Draft resolution on Strengthening Local Production of Medicines and Other Health Technologies to Improve Access, Dec 04,2020 – WHO Resolution on Strengthening… Continue Reading →

Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

Posted on March 12, 2021 by Arianna Schouten

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading →

10 March 2021: South Africa raises the banner for the TRIPS waiver at the WTO

Posted on March 11, 2021 by Thiru

On 10 March 2021, the World Trade Organization’s (WTO) TRIPS Council addressed the proposal for a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (IP/C/W/669) under agenda item 12. This proposal is… Continue Reading →

Hungarian compulsory license for remdesivir raises a stir with BIO, PhRMA and the US Chamber of Commerce

Posted on March 8, 2021 by Thiru

Whilst TRIPS Council deliberations in 2020 witnessed some lively deliberations on the nature of legislative amendments to Hungary’ special legal order (State of Danger) to enable the provision of a “compulsory licence regime for public health purposes”, Hungary’s recent decision… Continue Reading →

KEI Response to Questions from USTR on Special 301 – March 5, 2021

Posted on March 8, 2021 by KEI Staff

On Friday, March 5, 2021, Knowledge Ecology International (KEI) submitted written responses to questions from USTR on Special 301. The pdf version of KEI’s written submission can be found here.

23 February 2021: South Africa’s interventions at the WTO TRIPS Council

Posted on March 1, 2021 by Thiru

On 23 February 2021, South Africa delivered two detailed statements at the WTO TRIPS Council’s most recent deliberations on a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 (IP/C/W/669). South Africa did… Continue Reading →

Incoming WTO Director-General calls for ‘third way’ towards scaling up manufacturing of COVID-19 vaccines

Posted on February 19, 2021 by Thiru

On Monday, 15 February 2021, the World Trade Organization’s General Council, “agreed by consensus to select Ngozi Okonjo-Iweala of Nigeria as the organization’s seventh Director-General” (Source: History is made: Ngozi Okonjo-Iweala chosen as Director-General, 15 February 2021). Dr Ngozi is… Continue Reading →

Categories